Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...

For Hoosiers seeking a fresh start or a pathway to a fulfilling career, the Lilly Scholars at Ivy Tech scholarships offer a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...